CompuGroup Medical (COP) Q4 2024 earnings summary

Executive summary

• 2024 was a year of transition with a new CEO, a focus on customer centricity, operational excellence, innovation, and strategic acquisitions including Pridok, Emento Apps, and CPS Concept.

• The company strengthened its market position in Northern Europe and France, enhanced its product portfolio, and prioritized IT security, achieving C5 attestation.

• AI and cloud-based solutions such as CGM One and CGM Stella were launched, supporting ambulatory and pharmacy customers.

• A new strategic partnership was formed with CVC Capital Partners, which acquired nearly 22% stake, launched a voluntary public tender offer, and plans a delisting offer in Q2 2025.

• The company emphasized operational excellence, customer centricity, and portfolio expansion.

Financial highlights

• FY 2024 revenues were €1,154m, down 3% year-over-year; organic revenue declined by 2% but recurring revenues grew by 5% to €854m, now representing 74% of total revenues.

• Adjusted EBITDA was €225 million, with a margin of 19%, down 3 percentage points and 15% from the prior year.

• Adjusted EPS was €1.27, down from €2.06 in FY 2023 and below guidance due to higher tax payments.

• Free cash flow was €66 million, exceeding revised guidance but below the prior year due to lower one-off revenues, restructuring, and higher tax payments.

• Proposed dividend of €0.05 per share, down from €1.00 last year, to prioritize investment in innovation and growth.

Outlook and guidance

• Organic revenue for 2025 is expected to grow in the low- to mid-single digit percentage range, with recurring revenues and adjusted EBITDA also expected to increase.

• Free cash flow is expected to improve in 2025, supported by working capital measures.